Advaxis has successfully created a new live Listeria-based vaccine that combines the immune activation of Advaxis’s Listeria platform with the antigen p53 tumor target (Adxs-LmddA159). Adxs-LmddA159 is an attenuated live Listeria, which can deliver the fusion protein LLO-p53 into the cells of the immune system for antigen presentation.
Advaxis’s unique approach using Listeria as an antigen delivery system provides a method to deliver p53 into antigen processing pathways in immune cells resulting in strong T cell responses, which ultimately will cause the eradication of tumors expressing abnormally high levels of the targeted p53 protein.
Thomas Moore, chairman and CEO of Advaxis, said: “We are delighted to be collaborating with such a distinguished cancer research institute. We hope this research will lead to an important new cancer immunotherapy.”